Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study

BACKGROUND: Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult‐to‐treat patient. Brexpiprazole is a serotonin–dopamine activity modulator: a partial agonist at 5‐HT(1A) and dopamine D(2) receptors at similar potency, and an antagonist at 5‐HT(2A) and noradrenalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Lori L., Ota, Ai, Perry, Pamela, Tsuneyoshi, Kana, Weiller, Emmanuelle, Baker, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064333/
https://www.ncbi.nlm.nih.gov/pubmed/27781135
http://dx.doi.org/10.1002/brb3.520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064333/
https://www.ncbi.nlm.nih.gov/pubmed/27781135
http://dx.doi.org/10.1002/brb3.520

Ejemplares similares